Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab vs placebo in unresectable malignant mesothelioma (2nd/3rd line)
2024-511841-20-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in pleural mesothelioma and peritoneal mesothelioma comparing Tremelimumab with Placebo (2 arms). Primary endpoint: Overall survival (OS). Planned start Jul 2024; status: authorised.
02
Drugs
tremelimumab
03
Conditions
pleural mesotheliomaperitoneal mesothelioma
Beyond the preview
Go deeper on 2024-511841-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511841-20-00.